KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAsset Writedowns and ImpairmentBeginning Cash BalanceCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amneal Pharmaceuticals (AMRX) Change in Accured Expenses: 2017-2025

Historic Change in Accured Expenses for Amneal Pharmaceuticals (AMRX) over the last 8 years, with Sep 2025 value amounting to $69.7 million.

  • Amneal Pharmaceuticals' Change in Accured Expenses rose 48.87% to $69.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $69.0 million, marking a year-over-year decrease of 53.73%. This contributed to the annual value of $235.1 million for FY2024, which is 348.96% up from last year.
  • Amneal Pharmaceuticals' Change in Accured Expenses amounted to $69.7 million in Q3 2025, which was up 52.88% from $45.6 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Change in Accured Expenses ranged from a high of $322.7 million in Q2 2022 and a low of -$150.5 million during Q1 2023.
  • Moreover, its 3-year median value for Change in Accured Expenses was $45.6 million (2025), whereas its average is $13.0 million.
  • The largest annual percentage gain for Amneal Pharmaceuticals' Change in Accured Expenses in the last 5 years was 1,905.87% (2022), contrasted with its biggest fall of 828.86% (2022).
  • Amneal Pharmaceuticals' Change in Accured Expenses (Quarterly) stood at -$11.1 million in 2021, then tumbled by 402.74% to -$55.9 million in 2022, then skyrocketed by 64.63% to -$19.8 million in 2023, then soared by 435.29% to $66.3 million in 2024, then soared by 48.87% to $69.7 million in 2025.
  • Its Change in Accured Expenses stands at $69.7 million for Q3 2025, versus $45.6 million for Q2 2025 and -$112.6 million for Q1 2025.